Litigation Details for Takeda Pharmaceutical Co. v. Zydus Pharmaceuticals USA (Fed. Cir. 2013)

Takeda Pharmaceutical Co. v. Zydus Pharmaceuticals USA (Fed. Cir. 2013)

Docket		Date Filed	2013-05-15
Court	Court of Appeals for the Federal Circuit	Date Terminated	2014-02-20
Cause		Assigned To
Jury Demand		Referred To
Patents	6,328,994; 7,399,485; 7,431,942; 7,875,292
Link to Docket	External link to docket

Details for Takeda Pharmaceutical Co. v. Zydus Pharmaceuticals USA (Fed. Cir. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-05-15				External link to document

Litigation summary and analysis for: Takeda Pharmaceutical Co. v. Zydus Pharmaceuticals USA (Fed. Cir. 2013)

Last updated: April 25, 2026

Takeda v. Zydus Pharmaceuticals USA (13-1406): Litigation Summary, Patent Posture, and Strategic Implications

What case is 13-1406 and who are the parties?

Takeda Pharmaceutical Co. and related Takeda entities sued Zydus Pharmaceuticals USA and related Zydus entities in a Hatch-Waxman framework. The matter is docketed as 13-1406 in the US Court of Appeals for the Federal Circuit (Fed. Cir.). The case centers on Takeda’s patent rights asserted against Zydus’s generic entry.

Parties

• Plaintiff/Appellant: Takeda Pharmaceutical Co.
• Defendant/Appellee: Zydus Pharmaceuticals USA (and related defendants)

Forum

• Court: United States Court of Appeals for the Federal Circuit
• Docket: 13-1406
• Caption: Takeda Pharmaceutical Co. v. Zydus Pharmaceuticals USA

What did the litigation turn on procedurally?

Fed. Cir. appeals in ANDA patent disputes typically hinge on (1) claim construction, (2) infringement and invalidity findings, and (3) whether the procedural posture permits review of particular issues (including jurisdictional questions and appealability standards). In 13-1406, the appellate record addresses the underlying district court determinations and preserves the Federal Circuit’s standard approach: construction and infringement/validity analyses are reviewed under the relevant claim-by-claim framework.

Litigation posture (high-level)

• Takeda asserted patents against Zydus’s ANDA-related conduct.
• The district court ruled on infringement and/or validity.
• Zydus appealed and/or Takeda appealed.
• Fed. Cir. issued a decision resolving the appealed issues under Federal Circuit standards.

Which patents and product context does 13-1406 involve?

The docket number alone does not specify the asserted patents in the appellate caption. A complete, accurate litigation analysis requires the specific asserted patent numbers and the drug/product for which Zydus filed its ANDA or sought approval. No complete patent identity or product mapping is provided in the prompt, and the case details needed for a correct summary of the litigation’s substance are not present in the information available here.

Result: A complete and accurate “litigation summary and analysis” cannot be produced under the constraint that only sufficient information may be used to make a complete and accurate response.

What is the decision outcome for 13-1406?

A complete outcome analysis also requires the Fed. Cir. disposition (affirmed/reversed/vacated), the panel’s reasoning, and the status of each asserted claim (infringed/invalid/not reached). That information is not included in the provided prompt.

Result: An outcome and reasoning analysis cannot be issued accurately.

What is actionable from this docket for R&D and licensing?

Strategic takeaways in Takeda-versus-generic patent litigation depend on:

• which claims survived construction,
• the validity theory credited by the court (anticipation, obviousness, written description/enablement, indefiniteness, prosecution history estoppel, etc.),
• whether design-around space was preserved or foreclosed,
• and how the court treated generic design choices (formulation, polymorph, solvate, salts, release profile, stability, or method-of-use elements).

Those elements require case-specific holdings and claim-level mapping that are not contained in the prompt.

Result: No defensible, decision-grade strategic guidance can be issued without the missing holdings, asserted patents, and product context.

---

Key Takeaways

• 13-1406 is a Federal Circuit appeal in a Takeda v. Zydus Hatch-Waxman dispute, but the prompt does not provide the case’s dispositive holdings, asserted patent numbers, or product context required for a complete, accurate litigation summary and analysis.
• Claim-level and validity-theory takeaways depend on details not present here (asserted patents, construction results, infringement/invalidity outcomes, and the specific rationale).
• Business conclusions cannot be made reliably (licensing posture, design-around feasibility, and claim strategy) without the decision’s substance.

---

FAQs

1. What court decided 13-1406?
   The dispute is docketed in the US Court of Appeals for the Federal Circuit.

2. Who are the parties in Takeda v. Zydus Pharmaceuticals USA (13-1406)?
   Takeda Pharmaceutical Co. versus Zydus Pharmaceuticals USA and related entities.

3. Is this an ANDA Hatch-Waxman case?
   The docket corresponds to a Hatch-Waxman-style patent dispute as reflected by the parties and typical Federal Circuit posture, but the prompt does not include the asserted product or patents.

4. What patents were asserted in 13-1406?
   Not specified in the provided information.

5. What was the Federal Circuit’s disposition?
   Not specified in the provided information.

---

References

[1] Takeda Pharmaceutical Co. v. Zydus Pharmaceuticals USA, Fed. Cir. docket 13-1406.